Evotec 9M Revenue Tops Expectations; FY26 Guidance Reaffirmed
Summary
Evotec reported preliminary 9M 2026 revenue of ~€465M and adjusted EBITDA of ~-€42.8M, above market expectations, and reaffirmed full-year 2026 guidance.
Key Events · Earnings and Guidance · EVO
-
9M Revenue Beats Expectations
Preliminary 9M 2026 Group revenues of approximately €465.0 million came in above current market expectations, with the variance driven largely by the phasing of consensus estimates.
-
Adjusted EBITDA Still Negative
Preliminary 9M 2026 adjusted Group EBITDA was approximately -€42.8 million, reflecting continued operating losses despite the revenue beat.
-
FY26 Guidance Reaffirmed
Full-year 2026 guidance reaffirmed: Group revenues of €570-610 million (€595-635 million at CER) and adjusted Group EBITDA of -€70 to -€105 million (-€60 to -€90 million at CER).
-
Full Results Due November 5
Full Q3 and 9M 2026 financial results will be published on November 5, 2026, as scheduled.
Analysis · EVO · Life Sciences
Preliminary nine-month revenue of approximately €465 million and adjusted EBITDA of approximately -€42.8 million came in above market expectations, with the beat driven largely by the phasing of consensus estimates rather than a fundamental improvement. The company reaffirmed full-year 2026 guidance of €570-610 million in revenue and -€70 to -€105 million in adjusted EBITDA, signaling management sees no change to the underlying trajectory despite the stronger-than-expected nine-month print. This matters because Evotec is still absorbing a €168.6 million H1 net loss and Horizon restructuring costs, so confirmation that the full-year outlook is intact provides some stability, though the negative EBITDA range underscores continued operating losses.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVO was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.2M. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.